Sign inJoin waitlistJoin the waitlist

AZ

Alexandra Zimmer

Associate Professor of Medicine, Division of Hematology/Medical Oncology, School of Medicine · Oregon Health & Science University

Credentials: · · · · · ·

History

Oregon Health & Science University
Present

Hematology and Medical Oncology
Clinical Center at the National Institutes of Health
2012–2015
MedStar Washington Hospital Center
2009–2012
Hospital de Clínicas de Porto Alegre
2003–2005
Faculdade de Medicina da Universidade Federal do Rio Grande do Sul
1995–1999

Research

Safety and Clinical Activity of the Programmed Death-Ligand 1 Inhibitor Durvalumab in Combination With Poly (ADP-Ribose) Polymerase Inhibitor Olaparib or Vascular Endothelial…
Journal of Clinical Oncology · 2017 · 203 citations
Combination of PARP Inhibitor Olaparib, and PD-L1 Inhibitor Durvalumab, in Recurrent Ovarian Cancer: a Proof-of-Concept Phase II Study
Clinical Cancer Research · 2020 · Co-first of 18 authors · 189 citations
Prexasertib, a cell cycle checkpoint kinase 1 and 2 inhibitor, in BRCA wild-type recurrent high-grade serous ovarian cancer: a first-in-class proof-of-concept phase 2 study
The Lancet Oncology · 2018 · 187 citations

JL
Jung-Min Lee
7 papers
SL
Stanley Lipkowitz
7 papers
Christina Annunziata
6 papers
Amy Clark
3 papers
Angela DeMichele
3 papers
Ashley Cimino-Mathews
3 papers
Claudine Isaacs
3 papers
Elizabeth Swisher
3 papers
Hope Rugo
3 papers
Laura Esserman
3 papers
Paula Pohlmann
3 papers
Rebecca Shatsky
3 papers

Clinical trials

Abemaciclib and Niraparib Before Surgery for the Treatment of Hormone Receptor Positive HER2 Negative Breast Cancer
Principal investigator · Completed · Phase 1
OHSU Knight Cancer Institute
2021–2025
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Site PI · Recruiting · Phase 3
NRG Oncology
2023–2034
S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity
Site PI · Recruiting · Phase 3
SWOG Cancer Research Network
2017–2027
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
Site PI · Recruiting · Phase 2
QuantumLeap Healthcare Collaborative
2010–2031